w66最给利老牌

As one of the first Chinese pharmaceutical companies to participate in the annual JP Morgan Healthcare Conference, Sino Biopharm made another appearance at the conference at 9 a.m. EST on the 11th (10 p.m. BST on the 11th). In a video presentation, Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm, revealed that the company is expected to achieve double-digit revenue growth this year, driven by its core products such as PD1, Anlotinib and liver disease. The company's path to maintain sustainable growth in the future is clear, with up to 25 new products to be launched this year.

The 40th annual J.P. Morgan Healthcare Conference takes place January 10-13, 2022 EST. This is the 12th consecutive year that Sino Biopharm has been invited to present at the conference, ranking it among the top pharmaceutical companies in China. The J.P. Morgan Healthcare Conference is the largest industry event in the global biopharmaceutical health sector, and the largest and most informative healthcare investment and industry exchange and cooperation conference in the world. It is an excellent opportunity for top investors and highly influential companies in the health industry to share ideas.

Miss Tse, Theresa Y Y pointed out in his speech that Sino Biopharm's long-term mission is to become a leading global biopharmaceutical company, and that the company currently has more than 50 products with sales of more than RMB 100 million and plans to launch 20 to 30 new products each year. Among them, the star product, Anlotinib, will be approved for more new indications in the coming years to maintain strong growth revenues, and is expected to reach annual sales of approximately RMB 8 billion by 2028.

In the first half of 2021, Sino Biopharm achieved record high revenue of 14.354 billion yuan and net profit attributable to the mother company of 8.48 billion yuan, a significant increase of 583.6% year-on-year. After deducting the earnings of affiliates and joint ventures, which mainly gained returns from investment in Sinovac, net profit attributable to the mother company still increased by 22.9% year-on-year. The company maintained high double-digit growth in its 5 core areas of anti-tumor, parenteral nutrition, cardiovascular, respiratory, and orthopedics. Antineoplastic drugs became the number one business segment of Sino Biopharm, achieving revenue of 5 billion yuan in the first half, up 25% year-on-year. Miss Tse, Theresa Y Y said that more and more of the company's products benefited from centralized procurement and achieved rapid volume sales in the market.

Looking ahead, Miss Tse, Theresa Y Y noted that 2022 is the year of innovation for the Group's biologics, with Sino Biopharm launching its fourth innovative drug, recombinant eight factors, which is also the Group's second biologic drug. In addition, the Group will also launch its first biosimilar, adalimumab, in the coming weeks, which will have the opportunity to become a billion-dollar blockbuster. With the continuous progress in R&D in immuno-oncology, the company has increasingly realized that PD-1 may not be sufficient to fight some hard-to-treat cancers or "cold tumors" and has therefore started to lay out a next-generation I/O R&D pipeline as a way to complement the PD-1/PDL-1 product pipeline. Meanwhile, the company has initiated 2 head-to-head trials of PD-L1 and PD-1 in the first-line treatment of non-small cell lung cancer, one of which is head-to-head with a K-drug, and we will provide the latest data on the progress of the trials.

Mao Li, Chief Medical Officer of Sino Biopharm, said the Group has now unveiled its innovation program X-LAB, which aims to strengthen R&D capabilities at headquarters and accelerate its international presence. X-LAB will focus on molecules with potential peak sales of more than US$500 million in four therapeutic areas: oncology, lung disease, self-exemption and infectious diseases, with the goal of launching at least two potential top-selling products in the next five years. As part of its global BD initiative, the Group has also established InvoX, headquartered in London, to expand its global business development.